| April 06, 2022  Editor's Note: The message below from one of our partners is one we believe you should take a close look at. Dear Reader, It really is the biggest "hidden" opportunity on Wall Street. You see, while everyone else has been focused on crypto and pot stocks, we've been focused where no one else was looking: the biotech sector. As a result, we've had a different biotech stock taken over every 56 days... I'm truly grateful to be able to share my passion for biotech stocks with you (and I hope you've made some good money!). But today, I thought I'd take a moment to discuss where this big merger wave is coming from. It all started back in 1990 with the Human Genome Project (HGP), the international scientific research project dedicated to mapping the human genome. One of the many big benefits of the HGP was that for the first time ever, scientists were able to identify mutations linked to different forms of cancer. It wasn't long before they began to design new medications to address them. Now here's where it gets interesting... 75% of Cancer Drugs are Old Chemical Drugs Currently, 75% of all drugs to treat cancer are old chemical drugs. For example, the most popular drug to treat Leukemia is Cytarbine. Well guess what? Cytarbine was patented in 1960! A lot has changed in medicine since 1960! That's why the side effects are horrendous. They include bone marrow suppression, vomiting, diarrhea, liver problems, rash, ulcer formation in the mouth, and bleeding. Many of you know first-hand what I'm talking about. Going through chemo yourself or watching a loved one go through it is brutal. Absolutely brutal. This is what they mean by the expression "the chemo will get you before the cancer does." The good news is that that's now the "OLD WAY" of fighting cancer. Ever since the HGP, scientists have begun to develop molecular profiles of both the patient and the actual cancer. And they've been creating treatments based on those profiles. Precision-medicine. Now we have a whole "NEW WAY" of fighting cancer. Find out the Small Biotech scaring Big Pharma >>> How does that make this such a golden opportunity for takeover investors? It's simple... Worldwide spending on cancer therapies was about $140 billion in 2018, according to the American Association of Cancer Research. $105 billion, or 75% of that money was spent on the "OLD WAY" of treating cancer. $35 billion, or 25%, was spent on the "NEW WAY" of treating cancer. Well guess what? Those numbers are about to flip. It won't be long before 75% of all money for cancer therapies are spent on the "NEW WAY" of fighting cancer. It gets even better... Right now, Big Pharma (Pfizer, Eli Lilly, Glaxo, Bristol Meyers, etc) owns the "OLD WAY" oncology market. They have it locked down. But a new crop of small biotech companies is developing the "NEW WAY" oncology market. The Small Biotech Scaring Bristol Meyers One tiny biotech invented a breakthrough Leukemia treatment. This new medicine targets patients by their genetic profile. This new discovery threatens Big Pharma companies Bristol Meyers and Novartis. That makes this small biotech our top takeover target this month. Find out the rest of the story here >>> And guess what? Big Pharma has to buy Small Pharma if they want to keep their place in the market. That's why we've been able to rack up such great gains riding this wave - Pfizer bought "NEW WAY" firm Array Biopharma last month for $48 a share, a 144% gain from our recommended price of $18.90. Glaxo bought "NEW WAY" firm Tesaro in March for $74.96, a 93% gain from our recommended price of $38.41. Eli Lilly bought "NEW WAY" firm Loxo Oncology in January for $234.66, a 78% gain from our recommended price of $131.02. Illumina bought "NEW WAY" diagnostic firm Pacific Biosciences for $8, an 82% gain from our recommended price of $4.38. Want to know the next "NEW WAY" cancer drug company we think gets acquired? Find out the Small Biotech scaring Big Pharma >>> "The Buck Stops Here"
Trading involves risk. The information provided is NOT trading advice. Neither the Editors, the Publisher, nor any of their respective affiliates make any guarantee or other promise as to any results that may be obtained from the newsletter. Past performance is no guarantee of future performance. This recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability for any purchase or order made from any company or entity mentioned or recommended in this email. |
No comments:
Post a Comment